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Introduction
Randomised controlled trials (RCTs) represent the gold standard for gathering evidence about treatment effectiveness. Clinical trials seek to evaluate whether an intervention is effective and safe by comparing the effects of different alternatives on outcomes that are chosen to identify its benefits and harms. There is recognition that insufficient attention has been paid to the selection of proper outcomes to be used in clinical trials. Outcomes need to be relevant to patients, clinicians and policy-makers if the research is to influence practice.(1) A variety of outcomes can be selected for clinical trials, and these can be measured and reported in different ways. Problems arise if the selection, measurement and reporting of outcomes are inconsistent across clinical trials. First, important outcomes can be overlooked. If trialists are not aware of the importance of outcomes, it is likely that factors relating to the conduct of the trial, such as sample size, will determine which outcomes are measured. (2) A lack of standardisation may also lead to inefficient trials that involve multiple outcomes, larger than required sample sizes and multiple interpretations of results. (3) Secondly, meta-analysis will be difficult if different outcomes have been used. Even if the same outcomes are selected, they may be measured and analysed in different ways, and this too can impair the ability to synthesise their results. Finally, the third problem is selective outcome reporting bias (SORB) defined as the results-based selection for publication of a subset of the original measured outcome variables (4); in the absence of a set of core outcomes, trialists may decide to omit certain results from the final report.(2) Missing outcome data can affect systematic review in two ways. Publication bias, where a study is not published on the basis of its results, can lead to bias in the analysis of a particular outcome. Whereas, in a published study that has been identified by the reviewer, SORB can arise if the outcome had been measured and analysed but not reported.(5) The selection of appropriate outcomes in a trial, therefore, is crucial to the assessment of whether one intervention is better than another. One way to address these issues is the development of agreed standardised sets of outcomes, known as 'core outcome sets' (COS).(6) Some work has been undertaken to identify and validate the different patient reported outcome measures used in glaucoma trials. This previous effort provided a framework (and critique of existing tools) for selecting the core patient reported outcomes in glaucoma studies. (7) However, no attempt has been undertaken on the standardisation of the clinical outcome measures in glaucoma RCTs. Therefore, as a first step towards this goal, we aim to identify the breadth of clinical outcomes reported in glaucoma RCTs.
Methods
We conducted a systematic review of RCTs in glaucoma between January 2006 and March 2012. The reason of the time frame was that we were aiming to retrieve approximately 200
RCTs and we chose to start our search from the most recent ones. The n=200 is an arbitrary number that we proposed would be sufficient to identify the variation on outcomes reported in glaucoma RCTs. We searched for RCTs in glaucoma published in English only due to resources constraints; however there were no restrictions on the population studied, applied interventions, phases of the trials, or types of glaucoma. relating to glaucoma and randomised controlled trials was run. The abstracts were graded as "included", "possible" or "excluded". Abstracts were excluded if they were not evaluating glaucoma patients and/or the study design was not an RCT or not in English language. The investigators planned to identify further relevant RCTs (original studies) from references of the retrieved articles. All abstracts were reviewed independently by one reviewer (RI).
Another senior investigator (AAB) reviewed approximately 10% of all abstracts (400 consecutive abstracts) to evaluate agreement. This was a pragmatic approach that would have resulted in a larger duplicate grading if the agreement had been suboptimal.
Regarding the assessment of eligibility of RCTs full text copies were assessed by one reviewer (RI). A second masked senior reviewer (AAB) reviewed 10 consecutive papers.
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All clinical outcomes and variations of reporting were included in the analysis. We collected information on population, duration of follow up (months), sample size, type of intervention (medical, surgical, laser, others) and outcomes. We recorded which outcomes were considered to be primary or secondary and documented methods used to measure them, by whom, and when they were measured and analysed. Other types of outcomes such as patient reported outcome measures (PROMs), pharmacokinetic evaluation as well as economic outcomes were excluded. We agreed to contact trial authors as needed to clarify any details necessary to make a complete assessment of the study.
The data were initially abstracted on "Microsoft Office Access 2007" database and then statistics was run on Excel database. The data were tabulated in an excel sheet (Microsoft Corporation, Redmond, WA). Comprehensive pilot testing with two investigators (a clinician (RI) and a glaucoma expert (AAB)) was undertaken. As an effect, taxonomy of glaucoma outcomes was developed. Outcomes were grouped into one of eight main outcomes: intraocular pressure (IOP), visual field (VF), safety, haemodynamics, anatomical, aqueous humor (AH) dynamics, surgical-related, and persistence/ adherence to therapy.
Outcomes were further classified into different measures (specific measurement, specific metric or methods of aggregation). For example, for IOP, the pre-defined measures were: (1) IOP level, which was further subclassified into three possible measurements (Table) , (2 (Table) .
The pre-defined measures for the VF were: (1) evidence of progression of the VF, which was further subdivided into different metrics according to the methodology of measurement, (2) rate of VF progression/slope and (3) time to VF progression, which was also classified according to the methodology used. A similar classification of measures was used for the other clinical outcomes (see supplementary Table S1 (web only file) for classification).
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Designated primary and secondary outcomes were also identified. Descriptive statistical analysis was undertaken.
Results
The search identified 4323 potentially relevant abstracts. Of these, 238 abstracts were retrieved as "include" and 56 retrieved as "possible". From these abstracts two hundred and fifteen articles were included whereas 79 articles were excluded because either the study was not an RCT or it was an RCT but not for a glaucoma intervention. An additional 24 potential RCTs identified from the references with three of these were excluded for not being (Table) . Aqueous humor dynamics was only reported in five of the 233 RCTs (2%). On the other hand, safety outcomes were reported in 145 RCTs (62 %). There was a total of 346 times (36%) when safety measures were described (Table) . Visual acuity (VA) was the commonest among the safety measures (n=75, 8% of all measures) ( (Table) .
Systemic haemodynamics (blood pressure (BP) & pulse rate (PR) was the most commonly reported measure among the haemodynamics (n= 44, 5% of all measures) (Table) .
Primary outcomes were defined in 143 of the 233 RCTs (61%). Thirty one of the 143 studies (21.6%) determined more than one primary outcome; the total number of primary measures identified was 186, with IOP-related measures being the commonest (n=135, 73% of primary measures) (Table) . Mean IOP/ mean diurnal IOP/ 24-hour IOP was the commonest to be used as primary measure (n=51, 27% of all primary measures) (Table) .
Discussion
To the best of our knowledge, this is the first study to describe the selection of clinical outcomes in glaucoma RCTs. The study demonstrated a large variation in the way clinical outcomes were reported and a total lack of standardisation which may impair the ability to robustly evaluate the evidence of glaucoma interventions.
This variation was greatest for IOP and safety measures, the most commonly used clinical outcomes. Even though VF tests were uncommonly utilised as an outcome, a diversity of measurements was also apparent (with 12 different ways of evaluating VFs), whereas persistence/adherence to therapy has never been reported as an outcome.
Whilst the review was conducted in a rigorous, systematic manner, it is possible that some studies may have been missed by not searching the "grey" literature. The review had good external validity -the studies we identified included different glaucoma populations as well as different interventions. We excluded observational studies, but we were confident that these reports would be unlikely to add to the breadth of outcomes observed in this review. The outcomes reported by studies are the key for clinicians when making decisions about health care; however there is a general lack of consensus regarding the selection of outcomes in clinical settings, which affects trial design, analysis, as well as reporting. (16) Measuring outcomes that will not change healthcare decisions leads to a waste of resources and a failure to capitalise on the potential power of research to improve health care. (4) The difficulties caused by differences in outcome measurement are well known to systematic reviewers. For instance, the five most accessed and top cited Cochrane Reviews in 2009 all reported problems related to outcomes in eligible trials due to inconsistencies in the outcomes reported in the primary reports. (4) There is still great uncertainty on how best to select the most appropriate outcomes for use in a clinical trial.(17) Some of the factors underlying this uncertainty may include ambiguity regarding which outcomes are of relevance to patients, unknown performance characteristics of potential outcomes(e.g. reliability), or improvements in general care of patients with emergence of new technologies, with the result that previously used outcomes are no longer relevant. (18) The Core Outcome Measures in Effectiveness Trials (COMET) Initiative (19) was launched in January 2010 to address this lack of standardised outcomes in clinical trials and to develop a minimum set of measures named "core outcome sets" (COS), which include endpoints to be reported as a minimum. There is an expectation that the core outcomes will be reported to allow the results of studies to be combined as appropriate; and that researchers will continue to collect other outcomes as well. (6) . If the outcomes in the COS are reported then reviewers or people looking at studies in isolation, will always have access to the same set of key data. (6) To solve the issue of outcome heterogeneity, we aim to reach consensus on important In summary, the selection of outcomes and their measures was inconsistent among glaucoma RCTs. In addition, there was a wide variety of description within individual clinical outcomes. There is an obvious need to define a core clinical outcome dataset for glaucoma trials. 
